

# Alopecia Treatment Pipeline Review H1 2016

*Global Alopecia Drugs and Companies Pipeline Review H1 2016*

PUNE, INDIA, August 30, 2016

/EINPresswire.com/ -- Summary

'[Alopecia](#) - Pipeline Review, H2 2016', provides an overview of the Alopecia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects.

Complete report details @

<https://www.wiseguyreports.com/reports/619287-alopecia-pipeline-review-h2-2016>



Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/619287-alopecia-pipeline-review-h2-2016>

## Scope

- The report provides a snapshot of the global therapeutic landscape of Alopecia
- The report reviews pipeline therapeutics for Alopecia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product

description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Alopecia therapeutics and enlists all their major and minor projects
- The report assesses Alopecia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Alopecia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alopecia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/619287-alopecia-pipeline-review-h2-2016>

Key points in table of content

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Alopecia Overview 8

Therapeutics Development 9

Pipeline Products for Alopecia - Overview 9

Pipeline Products for Alopecia - Comparative Analysis 10

Alopecia - Therapeutics under Development by Companies 11

Alopecia - Therapeutics under Investigation by Universities/Institutes 13

Alopecia - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Alopecia - Products under Development by Companies 17

Alopecia - Products under Investigation by Universities/Institutes 20

Alopecia - Companies Involved in Therapeutics Development 21

Ache Laboratorios Farmaceuticos S/A 21

Aclaris Therapeutics, Inc. 22

Allergan Plc 23

Almirall, S.A. 24

AndroScience Corporation 25  
Berg LLC 26  
BiologicsMD, Inc. 27  
Bristol-Myers Squibb Company 28  
Concert Pharmaceuticals, Inc. 29  
Diffusion Pharmaceuticals Inc. 30  
Follicum AB 31  
Handok Inc. 32  
Histogen, Inc. 33  
Hyundai Pharmaceutical Co., Ltd. 34  
Incyte Corporation 35  
Kuhnil Pharmaceutical Co., Ltd. 36  
Lee's Pharmaceutical Holdings Limited 37  
LEO Pharma A/S 38  
NovaLead Pharma Pvt. Ltd. 39  
Novartis AG 40  
Panacea Biotec Limited 41  
Quark Pharmaceuticals, Inc. 42  
RepliCel Life Sciences, Inc. 43  
RXi Pharmaceuticals Corporation 44  
Sucampo Pharmaceuticals, Inc. 45  
SWITCH Biotech LLC 46  
Taisho Pharmaceutical Holdings Co., Ltd. 47  
TetraLogic Pharmaceuticals 48  
Tigo GmbH 49  
Valeant Pharmaceuticals International, Inc. 50  
Vida Therapeutics Inc. 51  
Alopecia - Therapeutics Assessment 52  
Assessment by Monotherapy Products 52  
Assessment by Target 53  
Assessment by Mechanism of Action 56  
Assessment by Route of Administration 59  
Assessment by Molecule Type 61  
Drug Profiles 63  
abatacept - Drug Profile 63  
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and  
Oncology - Drug Profile 68  
Antisense Oligonucleotide to Antagonize Androgen Receptor for Alopecia - Drug Profile 69  
ASCJ-9 - Drug Profile 70  
ATI-50001 - Drug Profile 72  
ATI-50002 - Drug Profile 73  
bimatoprost - Drug Profile 74  
BMD-1141 - Drug Profile 76  
BMD-1341 - Drug Profile 77  
BMD-2341 - Drug Profile 78  
BQ-A - Drug Profile 79  
BRM-421 - Drug Profile 80  
calcitriol - Drug Profile 81  
CB-0301 - Drug Profile 82  
CTP-543 - Drug Profile 84  
DHL-HisZnNa - Drug Profile 85  
diphencyprone - Drug Profile 86

finasteride - Drug Profile 88  
finasteride - Drug Profile 89  
FOL-005 - Drug Profile 90  
FS-2 - Drug Profile 93  
Hair Stimulating Complex - Drug Profile 94  
HL-5945 - Drug Profile 96  
HTB-005 - Drug Profile 97  
interferon beta-1b - Drug Profile 98  
KI-1104 - Drug Profile 99  
KI-1105 - Drug Profile 100  
LEO-124249 - Drug Profile 101  
minoxidil - Drug Profile 102

Buy this report @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=619287](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619287)

Norah Trent  
wiseguyreports  
+1 646 845 9349 / +44 208 133 9349  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.